phosphonoacetic acid has been researched along with Acquired Immune Deficiency Syndrome in 125 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 9.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 9.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.07 | Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 9.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "The administration of foscarnet decreases the rate of progression of cytomegalovirus retinitis in persons with AIDS." | 9.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "These results suggest that for patients with AIDS, and cytomegalovirus retinitis, treatment with foscarnet offers a survival advantage over treatment with ganciclovir, although the patients may not tolerate foscarnet as well as ganciclovir." | 9.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 8.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 7.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied." | 7.68 | Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 7.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Foscarnet, administered via a central line, was used for the treatment of 18 episodes of cytomegalovirus (CMV) esophageal ulceration in 15 patients, and in the treatment of 27 episodes of CMV colitis in 22 patients." | 7.68 | Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. ( Connolly, GM; Gazzard, BG; Hawkins, DA; Nelson, MR, 1991) |
| "The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells." | 7.67 | HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989) |
| "To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 7.67 | Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 7.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 6.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Treatment with Foscarnet may be initially effective, but does not eliminate cytomegalovirus infection." | 6.66 | Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate). ( Barrison, I; Boylston, A; Forster, S; Jeffries, DJ; Pinching, AJ; Thom, S; Unwin, R; Weber, JN, 1987) |
| "Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay." | 5.28 | [Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 5.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "Foscarnet has been shown to be active in vitro against the human immunodeficiency virus and all human herpesviruses including cytomegalovirus (CMV)." | 5.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 5.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 5.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 5.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "These results suggest that for patients with AIDS, and cytomegalovirus retinitis, treatment with foscarnet offers a survival advantage over treatment with ganciclovir, although the patients may not tolerate foscarnet as well as ganciclovir." | 5.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.07 | Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992) |
| "The administration of foscarnet decreases the rate of progression of cytomegalovirus retinitis in persons with AIDS." | 5.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Foscarnet was administered by continuous intravenous infusion in 15 patients with the acquired immunodeficiency syndrome (AIDS) in an open, uncontrolled study." | 5.06 | The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. ( Faber, V; Gaub, J; Gerstoft, J; Hofmann, B; Lernestedt, JO; Lindhardt, BO; Mathiesen, LR; Pedersen, C; Poulsen, AG; Ulrich, K, 1987) |
| " The antiviral agents ganciclovir and foscarnet are effective against CMV retinitis and gastrointestinal diseases, although dose-limiting adverse effects and the need for long-term maintenance therapy may hinder their use in many patients." | 4.78 | Treatment and prophylaxis of cytomegalovirus disease. ( Jacobson, PA; Levinson, ML, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 4.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "In an AIDS patient who had repeated successful treatment with acyclovir in his history, erosive herpes perianalis with herpes proctitis appeared, which persisted over several weeks." | 3.68 | [Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS]. ( Bratzke, B; Ehlers, G; Orfanos, CE; Stavermann, T, 1991) |
| "Foscarnet and ganciclovir appear to be of similar effectiveness in halting active infection when given as induction therapy and in forestalling progression of disease when given as maintenance therapy in persons with AIDS who have cytomegalovirus (CMV) retinitis." | 3.68 | Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary. ( Balfour, HH; Drew, WL; Hardy, WD; Heinemann, MH; Polsky, B, 1992) |
| "Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha." | 3.68 | Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. ( Birch, CJ; Doherty, R; Hayes, K; Lucas, CR; Mijch, A; Tachedjian, G; Tyssen, DP, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 3.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 3.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "To determine whether foscarnet has potential efficacy in the treatment of acyclovir-resistant mucocutaneous varicella-zoster infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 3.68 | Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. ( Berger, TG; Biron, KK; Gilson, I; Mills, J; Safrin, S; Wofsy, CB; Wolfe, PR, 1991) |
| "Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied." | 3.68 | Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990) |
| "Foscarnet, administered via a central line, was used for the treatment of 18 episodes of cytomegalovirus (CMV) esophageal ulceration in 15 patients, and in the treatment of 27 episodes of CMV colitis in 22 patients." | 3.68 | Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. ( Connolly, GM; Gazzard, BG; Hawkins, DA; Nelson, MR, 1991) |
| "Acyclovir (ACV)-resistant herpes simplex virus type 2 (HSV-2) was isolated from a patient with acquired immunodeficiency syndrome after long-term but intermittent ACV therapy." | 3.68 | Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. ( Birch, CJ; Doherty, RR; Gust, ID; Hayes, K; Tachedjian, G, 1990) |
| "The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells." | 3.67 | HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989) |
| "To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 3.67 | Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 3.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| "Foscarnet was administered as a continuous infusion of 200 mg/kg (prior to 1988) or as an intermittent infusion of 60 mg/kg t." | 2.67 | Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet. ( Blanshard, C, 1992) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 2.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Treatment with Foscarnet may be initially effective, but does not eliminate cytomegalovirus infection." | 2.66 | Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate). ( Barrison, I; Boylston, A; Forster, S; Jeffries, DJ; Pinching, AJ; Thom, S; Unwin, R; Weber, JN, 1987) |
| "CMV disease is a major problem in AIDS, though with a different profile from that seen in other immunosuppressed patients." | 2.38 | Cytomegalovirus infection in the acquired immune deficiency syndrome. ( Pinching, AJ, 1989) |
| " Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir." | 2.38 | Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991) |
| " The serious toxicity associated with zidovudine has led researchers to develop safer dosage regimens." | 2.38 | Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease. ( Cersosimo, RJ; Matthews, SJ; Spivack, ML, 1991) |
| "How to treat cytomegalovirus infections in patients infected with the human immunodeficiency virus constitutes one of the best examples of the quandaries engendered by these advances, and the topic is reviewed in this first AIDS Commentary update." | 2.38 | Cytomegalovirus infection in patients with AIDS. ( Drew, WL, 1992) |
| "The end-stage of these infections, acquired immune deficiency syndrome (AIDS), was first recognised in 1981, and the causative agent isolated in 1983." | 2.37 | Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date. ( Kaplan, JC; Sandström, EG, 1987) |
| " An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy." | 2.37 | Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. ( Jacobson, MA; Mills, J, 1988) |
| "Cytomegalovirus retinitis is probably the result of hematogenous spread of the virus to the retina after systemic reactivation of a latent cytomegalovirus infection." | 2.37 | The diagnosis of cytomegalovirus retinitis. ( Bloom, JN; Palestine, AG, 1988) |
| "Foscarnet was distributed to the cerebrospinal fluid in a concentration varying from 13 to 68% of the simultaneous concentration in plasma." | 1.28 | Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. ( Bergdahl, S; Movin, G; Ogenstad, S; Saarimäki, M; Sjövall, J, 1989) |
| " TPFA had a mean terminal plasma half-life of 42 min, a total clearance of 4." | 1.28 | Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat. ( Bai, SA; de Vera, CC; Loo, TL; Nelson, PD; Straw, JA; Tompkins, WA, 1992) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 1.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "Foscarnet has been shown to be active in vitro against the human immunodeficiency virus and all human herpesviruses including cytomegalovirus (CMV)." | 1.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| "Fifty AIDS patients were investigated for human cytomegalovirus (HCMV) viraemia when potentially HCMV-related clinical symptoms or syndromes were observed." | 1.28 | Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. ( Gaballo, A; Gerna, G; Milanesi, G; Parea, M; Percivalle, E; Zavattoni, M; Zipeto, D, 1991) |
| "Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay." | 1.28 | [Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992) |
| " The combined effect of ddNTPs and the pyrophosphate analog phosphonoformate (PFA) on HIV reverse transcriptase was also examined, and inhibition by PFA in combination with ddTTP or AZTTP was mutually exclusive." | 1.28 | Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate. ( Cheng, YC; Starnes, MC, 1989) |
| "Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| " Therefore we began treatment with trisodium phosphonoformate (Foscavir) at a dosage of 60 mg/kg body weight per day (3 weeks), continuing with maintenance therapy at 90 mg/kg body weight per day (7 days a week)." | 1.28 | [Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis]. ( Gümbel, H; Helm, EB; Ohrloff, C; Schalnus, R, 1991) |
| " Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain." | 1.27 | Treatment of CMV retinitis in an AIDS patient. ( Acheson, JF; Bradbeer, C; Shah, SM; Spalton, DJ; Thin, RN, 1987) |
| "Foscarnet (FC) is a new antiviral agent which has been recently proposed for the treatment of severe cytomegalovirus (CMV) infections in immunocompromised patients." | 1.27 | Acute renal failure induced by foscarnet: 4 cases. ( Baumelou, A; Cacoub, P; Deray, G; Gentilini, M; Jacobs, C; Le Hoang, P; Rousselie, R; Rozenbaum, W; Soubrie, C, 1988) |
| "Foscarnet was administered to eight AIDS patients for suspected cytomegalovirus (CMV) pneumonitis as a continuous intravenous infusion for a minimum of 8 days." | 1.27 | Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. ( Anderson, MG; Chanas, AC; Ellis, ME; Farthing, C; Gazzard, BG, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (35.20) | 18.7374 |
| 1990's | 81 (64.80) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Healy, B | 1 |
| Hirsch, MS | 3 |
| Masur, H | 1 |
| Heinemann, MH | 2 |
| Polis, MA | 2 |
| Jabs, DA | 1 |
| Jansen, CL | 1 |
| Maris-Tegeler, WG | 1 |
| Wertheim-van Dillen, PM | 1 |
| Frissen, PH | 2 |
| Weiland, HT | 1 |
| van der Noordaa, J | 1 |
| Evans, JK | 1 |
| Scoular, A | 1 |
| Miller, RF | 1 |
| Drew, WL | 3 |
| Nicoli, F | 1 |
| Dhiver, C | 1 |
| Chave, B | 1 |
| Poizot-Martin, I | 1 |
| Gastaut, JA | 1 |
| Gastaut, JL | 1 |
| Wilson, RJ | 1 |
| Skolnik, PR | 1 |
| Deray, G | 2 |
| Katlama, C | 3 |
| Jacobs, C | 2 |
| Bachman, DM | 1 |
| Peters, M | 1 |
| Timm, U | 1 |
| Schürmann, D | 1 |
| Pohle, HD | 1 |
| Ruf, B | 1 |
| Dohin, E | 1 |
| Caumes, E | 1 |
| Cochereau-Massin, I | 1 |
| Brancon, C | 1 |
| Robinet, M | 2 |
| Rogeaux, O | 1 |
| Dahan, R | 1 |
| Gentilini, M | 2 |
| Blanshard, C | 2 |
| Balfour, HH | 1 |
| Hardy, WD | 2 |
| Polsky, B | 1 |
| Jacobson, MA | 12 |
| Manji, H | 1 |
| Malin, A | 1 |
| Connolly, S | 1 |
| Birch, CJ | 2 |
| Tyssen, DP | 1 |
| Tachedjian, G | 2 |
| Doherty, R | 1 |
| Hayes, K | 2 |
| Mijch, A | 1 |
| Lucas, CR | 1 |
| Evans, LM | 1 |
| Grossman, ME | 1 |
| Cotte, L | 1 |
| Langlois, M | 1 |
| Trepo, C | 1 |
| Reddy, MM | 1 |
| Grieco, MH | 1 |
| McKinley, GF | 1 |
| Causey, DM | 1 |
| van der Horst, CM | 1 |
| Parenti, DM | 1 |
| Hooton, TM | 1 |
| Davis, RB | 1 |
| Levinson, ML | 1 |
| Jacobson, PA | 1 |
| Moyle, G | 1 |
| Harman, C | 1 |
| Mitchell, S | 1 |
| Mathalone, B | 1 |
| Gazzard, BG | 7 |
| Morris, DJ | 1 |
| Wood, CA | 1 |
| Enting, R | 1 |
| de Gans, J | 1 |
| Reiss, P | 2 |
| Jansen, C | 1 |
| Portegies, P | 1 |
| Straw, JA | 1 |
| Loo, TL | 1 |
| de Vera, CC | 1 |
| Nelson, PD | 1 |
| Tompkins, WA | 1 |
| Bai, SA | 1 |
| el-Chaar, GM | 1 |
| Schwenk, MH | 1 |
| Bardini, J | 1 |
| Caliendo, G | 1 |
| Frank, C | 1 |
| Profeta, LM | 1 |
| Talbot, KA | 1 |
| Cohen, H | 1 |
| Cox, SW | 1 |
| Wahren, B | 1 |
| Longuet, P | 1 |
| Leport, C | 1 |
| Feinberg, J | 1 |
| O'Donnell, JJ | 4 |
| Whitmore, PV | 1 |
| Miner, RD | 1 |
| Parenti, D | 1 |
| Safrin, S | 4 |
| Berger, TG | 1 |
| Gilson, I | 1 |
| Wolfe, PR | 1 |
| Wofsy, CB | 1 |
| Mills, J | 10 |
| Biron, KK | 1 |
| Nelson, MR | 2 |
| Connolly, GM | 2 |
| Hawkins, DA | 3 |
| Crumpacker, C | 1 |
| Chatis, P | 1 |
| Davis, R | 1 |
| Hafner, R | 1 |
| Rush, J | 2 |
| Kessler, HA | 1 |
| Landry, B | 1 |
| MacGregor, RR | 1 |
| Graziani, AL | 1 |
| Weiss, R | 1 |
| Grunwald, JE | 1 |
| Gambertoglio, JG | 1 |
| Palestine, AG | 2 |
| De Smet, MD | 1 |
| Baird, BF | 1 |
| Falloon, J | 1 |
| Kovacs, JA | 1 |
| Davey, RT | 1 |
| Zurlo, JJ | 1 |
| Zunich, KM | 1 |
| Davis, M | 1 |
| Marwick, C | 1 |
| Nightingale, SL | 1 |
| Minor, JR | 3 |
| Peters, BS | 2 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 1 |
| Harris, JR | 1 |
| Pinching, AJ | 4 |
| Lowenstein, W | 1 |
| Fadlallah, JP | 1 |
| Roudière, L | 1 |
| Deneux, C | 1 |
| Haas, C | 1 |
| Durand, H | 1 |
| Harb, GE | 1 |
| Bacchetti, P | 1 |
| Gerna, G | 2 |
| Zipeto, D | 1 |
| Parea, M | 1 |
| Percivalle, E | 1 |
| Zavattoni, M | 2 |
| Gaballo, A | 1 |
| Milanesi, G | 1 |
| Gümbel, H | 1 |
| Ohrloff, C | 1 |
| Schalnus, R | 1 |
| Helm, EB | 1 |
| Jenkins, RE | 1 |
| Barter, G | 1 |
| Hawkins, D | 1 |
| Chrisp, P | 1 |
| Clissold, SP | 1 |
| Söderlund, C | 1 |
| Bratt, G | 1 |
| Grützmeier, S | 1 |
| Rieger, A | 1 |
| Sandström, E | 4 |
| Sjunnesson, M | 1 |
| Matthews, SJ | 1 |
| Cersosimo, RJ | 1 |
| Spivack, ML | 1 |
| Bratzke, B | 1 |
| Orfanos, CE | 1 |
| Stavermann, T | 1 |
| Ehlers, G | 1 |
| Stellbrink, HJ | 1 |
| Albrecht, H | 1 |
| Löning, T | 1 |
| Greten, H | 1 |
| Bevilacqua, F | 1 |
| Marcello, A | 1 |
| Toni, M | 1 |
| Cusini, M | 1 |
| Zerboni, R | 1 |
| Palù, G | 1 |
| Baltz, JK | 2 |
| Van Der Pijl, JW | 1 |
| Hulsebosch, HJ | 1 |
| Van Den Tweel, JG | 1 |
| Lange, JM | 1 |
| Danner, SA | 1 |
| Gilquin, J | 1 |
| Weiss, L | 1 |
| Kazatchkine, MD | 1 |
| Lortholary, A | 1 |
| Raffi, F | 1 |
| Aubertin, P | 1 |
| Barrier, JH | 1 |
| Boibieux, A | 1 |
| Peyramond, D | 1 |
| Kennedy, P | 1 |
| Gallelli, J | 1 |
| Green, ST | 1 |
| Nathwani, D | 1 |
| Goldberg, DJ | 1 |
| Mack, DJ | 1 |
| Kennedy, DH | 1 |
| Youle, M | 1 |
| Chanas, A | 3 |
| Gazzard, B | 2 |
| Fanning, MM | 2 |
| Read, SE | 2 |
| Benson, M | 1 |
| Vas, S | 1 |
| Rachlis, A | 2 |
| Kozousek, V | 1 |
| Mortimer, C | 1 |
| Harvey, P | 1 |
| Schwartz, C | 1 |
| Chew, E | 2 |
| Farese, RV | 1 |
| Schambelan, M | 1 |
| Hollander, H | 1 |
| Stringari, S | 1 |
| Assaykeen, T | 1 |
| Follansbee, S | 1 |
| Doherty, RR | 1 |
| Gust, ID | 1 |
| Cotton, P | 1 |
| Kaplan, JC | 2 |
| De Clercq, E | 1 |
| Vogt, M | 1 |
| Schooley, RT | 2 |
| Pomerantz, RJ | 1 |
| Larder, BA | 1 |
| Darby, G | 1 |
| Richman, DD | 2 |
| Montefiori, DC | 1 |
| Robinson, WE | 1 |
| Mitchell, WM | 1 |
| Starnes, MC | 1 |
| Cheng, YC | 1 |
| Erlich, KS | 1 |
| Koehler, JE | 1 |
| Follansbee, SE | 1 |
| Drennan, DP | 2 |
| Gooze, L | 1 |
| MacPhail, LA | 1 |
| Greenspan, D | 1 |
| Schiødt, M | 1 |
| Sjövall, J | 2 |
| Bergdahl, S | 2 |
| Movin, G | 1 |
| Ogenstad, S | 2 |
| Saarimäki, M | 2 |
| Chatis, PA | 1 |
| Miller, CH | 1 |
| Schrager, LE | 1 |
| Crumpacker, CS | 1 |
| Lehoang, P | 1 |
| Girard, B | 1 |
| Marcel, P | 1 |
| Zazoun, L | 1 |
| Matheron, S | 1 |
| Rozenbaum, W | 2 |
| Morer, I | 1 |
| Lernestedt, JO | 2 |
| Aweeka, F | 2 |
| Gambertoglio, J | 2 |
| Wood, G | 1 |
| Whitby, M | 1 |
| Hogan, P | 1 |
| Frazer, I | 1 |
| Sandström, EG | 1 |
| Acheson, JF | 1 |
| Shah, SM | 1 |
| Spalton, DJ | 1 |
| Bradbeer, C | 1 |
| Thin, RN | 1 |
| Walmsley, SL | 1 |
| Vellend, H | 1 |
| Salit, I | 1 |
| Cacoub, P | 1 |
| Baumelou, A | 1 |
| Le Hoang, P | 2 |
| Soubrie, C | 1 |
| Rousselie, R | 1 |
| Yarchoan, R | 1 |
| Broder, S | 1 |
| Crowe, S | 1 |
| Levy, J | 1 |
| McManus, N | 1 |
| Miller, RG | 1 |
| Greco, C | 1 |
| Gonzales, MF | 1 |
| Bloom, JN | 1 |
| Wyngaarden, JB | 1 |
| Michon, C | 1 |
| Girard, PM | 1 |
| Ngovan, P | 1 |
| Simonpoli, AM | 1 |
| Beldekas, JC | 1 |
| Levy, EM | 1 |
| Black, P | 1 |
| Von Krogh, G | 1 |
| Sönnerborg, A | 1 |
| Larsson, A | 1 |
| Strannegard, O | 1 |
| Youle, MS | 1 |
| Clarbour, J | 1 |
| Youle, MM | 1 |
| Collins, P | 1 |
| Shanson, DC | 1 |
| Evans, R | 1 |
| Oliver, N | 1 |
| Lawrence, A | 1 |
| Heley, A | 1 |
| Hunt, AF | 1 |
| Jones, MT | 1 |
| Howkins, GJ | 1 |
| Weber, J | 1 |
| Farthing, CF | 1 |
| Dalgleish, AG | 1 |
| Clark, A | 1 |
| McClure, M | 1 |
| Gaub, J | 1 |
| Pedersen, C | 1 |
| Poulsen, AG | 1 |
| Mathiesen, LR | 1 |
| Ulrich, K | 1 |
| Lindhardt, BO | 1 |
| Faber, V | 1 |
| Gerstoft, J | 1 |
| Hofmann, B | 1 |
| Karlsson, A | 1 |
| Singer, DR | 1 |
| Fallon, TJ | 1 |
| Schulenburg, WE | 1 |
| Williams, G | 1 |
| Cohen, J | 1 |
| Brochard, L | 1 |
| Salmeron, S | 1 |
| Herve, P | 1 |
| Petitpretz, P | 1 |
| Boissonnas, A | 1 |
| Simonneau, G | 1 |
| Duroux, P | 1 |
| Weber, JN | 1 |
| Thom, S | 1 |
| Barrison, I | 1 |
| Unwin, R | 1 |
| Forster, S | 1 |
| Jeffries, DJ | 1 |
| Boylston, A | 1 |
| Farthing, C | 1 |
| Anderson, MG | 1 |
| Ellis, ME | 1 |
| Chanas, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component[NCT00000665] | 240 participants | Interventional | Completed | ||||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China[NCT02151240] | Phase 4 | 94 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine[NCT00000985] | Phase 3 | 26 participants | Interventional | Completed | |||
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
25 reviews available for phosphonoacetic acid and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Characteristics of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Cytomegalovirus infection in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Chorioretinitis; Cytomegalovirus Infections; Encephalitis; Fosca | 1992 |
Cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differe | 1992 |
Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1992 |
Foscarnet therapy for AIDS-related opportunistic herpesvirus infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Comb | 1992 |
Foscarnet-induced penile ulcer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment and prophylaxis of cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
New drugs on the horizon.
Topics: Acquired Immunodeficiency Syndrome; Aminosalicylic Acids; Antibodies, Monoclonal; Antibodies, Monocl | 1992 |
Foscarnet therapy in persons with AIDS: clinical research and management considerations. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Administration Schedule; Foscarnet; Human | 1992 |
[Prophylactic treatments of opportunistic infections in acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Male; | 1992 |
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; H | 1991 |
Foscarnet sodium.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Prospects of therapy for infections with human T-lymphotropic virus type III.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Antimony; Antiviral Agents; Combined Moda | 1985 |
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
Topics: Acquired Immunodeficiency Syndrome; Adsorption; Antibodies, Viral; Antigens, Viral; Aurintricarboxyl | 1986 |
Therapy of human immunodeficiency virus infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Foscarnet; Humans; Immunotherapy; Interferons; | 1987 |
Cotton-wool spots and cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Cytomegalovirus Infections; Diabetic Retinopathy; Dia | 1989 |
Cytomegalovirus infection in the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Addison Disease; Antiviral Agents; Colitis; Cytomegal | 1989 |
Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Forecasting; Foscarnet; Immunotherap | 1987 |
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
Progress in the development of antiviral therapy for HTLV-III-associated diseases.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; HIV; Humans; Phosphonoace | 1987 |
The diagnosis of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Diagnos | 1988 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; | 1988 |
[Treatment of cytomegalovirus infections in immunosuppressed patients].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
Antiviral drugs for AIDS. Current status and future prospects.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Humans; Interferon Type I | 1986 |
19 trials available for phosphonoacetic acid and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
The treatment of cytomegalovirus in AIDS--more than meets the eye.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; | 1992 |
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Dose-Response Relationship, D | 1992 |
Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1992 |
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1991 |
AIDS file.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Foscarnet versus ganciclovir in the management of cytomegalovirus disease in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonitis with foscarnet: a double-blind placebo controlled study.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; D | 1990 |
[Chemotherapy and immunoprophylaxis of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Foscarnet; HIV; Huma | 1986 |
From the National Institutes of Health. Progress in AIDS research.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1988 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; | 1988 |
Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antigens, Viral; Clinical Trials as Topic; | 1987 |
The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibodies, Viral; Clinical Trials as Topic; Foscarnet; H | 1987 |
Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate).
Topics: Acquired Immunodeficiency Syndrome; Adult; Clinical Trials as Topic; Colitis; Cytomegalovirus Infect | 1987 |
82 other studies available for phosphonoacetic acid and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthr | 1992 |
Foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Didanosine and foscarnet marketed for use by patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Didanosine; Foscar | 1992 |
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of cytomegalovirus retinitis--1992.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
[Acyclovir-resistant herpes simplex virus infections in immunocompromised patients].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Bone Transplantation; Drug R | 1992 |
Cytomegalovirus and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
[Regressive diffuse leukoencephalitis under foscarnet in an AIDS infected patient].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Encephalitis; Fosc | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1992 |
Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary.
Topics: Acquired Immunodeficiency Syndrome; Adult; Algorithms; Cytomegalovirus Infections; Foscarnet; Gancic | 1992 |
CMV polyradiculopathy in AIDS--suggestions for new strategies in treatment.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; Humans; Male; Nerv | 1992 |
Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Combined Modality Therapy; C | 1992 |
Herpes simplex virus infection during foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Foscarnet for CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Therap | 1992 |
Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Animals; Antiviral Agents; Biological Avai | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Fos | 1992 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1991 |
Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Cohort Studies; Drug Resista | 1991 |
Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Colitis; Cytomegalovirus Infections; Es | 1991 |
Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Cytomegalovirus In | 1991 |
National Eye Institute issues clinical alert about CMV retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Foscarnet approved for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1991 |
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |
[Prevention of genital erosions during treatments with foscarnet of cytomegalovirus infections in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1991 |
Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fos | 1991 |
Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
[Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Chorioretinitis; Cytomegalovirus Infections; D | 1991 |
Thromboembolic disease in AIDS is associated with cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1991 |
Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Seeing the way forward for treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1991 |
[Cytomegalovirus ileocolitis in patients with HIV infection is a treatable cause of severe abdominal problems].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cecum; Crohn Disease; Cytomegalovirus I | 1991 |
[Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Dose-Response Relationship, | 1991 |
Herpes simplex virus type-2 ulcers resistant to acyclovir in an AIDS patient--successful treatment with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Anus Diseases; Drug Resistan | 1991 |
Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Follow-Up Studies; | 1991 |
Foscarnet and extended survival in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Foscarnet; Phosphonoacetic Acid; Survival Rate | 1991 |
Generalised cutaneous rash associated with foscarnet usage in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Erythema; Foscarnet; Humans; Male; Phos | 1991 |
Foscarnet effective in acyclovir-resistant herpes.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1991 |
Foscarnet and penile ulceration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Herpes | 1990 |
Genital and oral erosions induced by foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Foscarnet; Genital Diseases, Male; Huma | 1990 |
Penile ulcerations with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1990 |
HIV-associated haemophagocytic syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Co | 1990 |
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Chromatography, Thin Layer; Drug Combinations; | 1990 |
Generalised cutaneous rash associated with foscarnet usage in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Drug Eruptions; Foscarnet; Ganciclovir; | 1990 |
Foscarnet therapy of cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1990 |
Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Diabetes In | 1990 |
Fixed drug eruption due to foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Erupti | 1990 |
Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet; | 1990 |
Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Aphidicolin; Deoxyguanosine; | 1990 |
Wider access provided to AIDS drugs with actions against HIV, CMV infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV Inf | 1990 |
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dideoxynucleosides; Drug Resistance; Fosca | 1989 |
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Alkaloids; Amphotericin B; Antiviral Agents; Drug Therapy, Combi | 1989 |
Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.
Topics: Acquired Immunodeficiency Syndrome; Dideoxynucleosides; Dinucleoside Phosphates; DNA Replication; DN | 1989 |
Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Candidiasis, Oral; Drug Resi | 1989 |
Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Creatine; Foscarnet; Humans; Infusions, | 1989 |
Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Creatine; Cytomegalovirus Infections; Drug Therapy, Combi | 1989 |
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Calcium; Cytomegalovirus Infections; Fo | 1989 |
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1989 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1989 |
Treatment of CMV retinitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1987 |
Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1988 |
Acute renal failure induced by foscarnet: 4 cases.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Chorioretinitis; C | 1988 |
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV; HI | 1988 |
Failure of antiviral therapy for acquired immunodeficiency syndrome-related cytomegalovirus myelitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Cytomegalovirus Infections; | 1988 |
In vitro effect of foscarnet on expansion of T-cells from people with LAS and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Colony-Forming Units Assay; Deltaretrovirus; Foscarnet; Humans; | 1985 |
Declining levels of HIV P24 antigen in serum during treatment with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Foscarnet; HIV; HIV Antigens; | 1988 |
Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine.
Topics: Acquired Immunodeficiency Syndrome; Amidines; Foscarnet; Humans; Hypocalcemia; Organophosphorus Comp | 1988 |
Acyclovir-resistant herpes in AIDS treated with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet; | 1988 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; HIV Antigens; Home | 1988 |
Effect of sodium phosphonoformate on blood group antibody detection.
Topics: Acquired Immunodeficiency Syndrome; Antibodies; Blood Grouping and Crossmatching; Coombs Test; Fosca | 1986 |
AIDS: the virus, antivirals and vaccines.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Genes, Viral; HIV; Humans | 1987 |
Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Bone and Bones; Calcium; Foscarnet; Glo | 1988 |
Foscarnet for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1985 |
[Importance of Foscarnet in the treatment of cytomegalovirus pneumopathy in a patient with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1986 |
Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1987 |